Disease progression increases the risk of skeletal-related events in patients with bone metastases from castration-resistant prostate cancer, lung cancer, or other solid tumors.
Baseline and disease progression characteristics may predict the risk of skeletal-related events (SREs) in patients with bone metastases from various solid tumors. Exploratory analysis of phase III trials compared zoledronic acid with placebo in patients with bone metastases from castration-resistant prostate cancer (N = 643) and lung cancer or other solid tumors (N = 773), adjusted for baseline and time-dependent disease parameters. In all models, more than three bone lesions at baseline correlated with the increased SRE risk. Bone and overall disease progression correlated with increased SRE risk. Overall, cancer progression correlated with increased SRE risks and zoledronic acid was associated with reduced SRE risks versus placebo.
Tchekmedyian
N Simon
NS
Pacific Shores Medical Group, Long Beach, California 90813, USA. simont@pacshoresoncology.com
Chen
Yin-Miao
YM
Saad
Fred
F
D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000473:pathology / Q000517:prevention & control / Q000556:secondary*; D004164:Diphosphonates / Q000627:therapeutic use; D018450:Disease Progression; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000150:complications* / Q000473:pathology / Q000601:surgery*; D008297:Male; D009369:Neoplasms / Q000150:complications / Q000473:pathology / Q000601:surgery; D009919:Orchiectomy; D010919:Placebos; D011471:Prostatic Neoplasms / Q000150:complications* / Q000601:surgery*; D012307:Risk Factors; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D010919:Placebos; D000077211:Zoledronic Acid